Country: Canada
Language: English
Source: Health Canada
ESTRADIOL (ESTRADIOL HEMIHYDRATE)
LUPIN PHARMA CANADA LIMITED
G03CA03
ESTRADIOL
1MG
TABLET
ESTRADIOL (ESTRADIOL HEMIHYDRATE) 1MG
ORAL
100
Prescription
ESTROGENS
Active ingredient group (AIG) number: 0106457003; AHFS:
APPROVED
2015-11-16
_LUPIN-ESTRADIOL (17β-estradiol) _ _Page 1 of 32 _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR LUPIN-ESTRADIOL 17β-estradiol Tablets, USP Tablets, 0.5 mg, 1 mg, 2 mg 17β-estradiol (as Estradiol Hemihydrate), Oral USP Estrogen Lupin Pharma Canada Limited 1111, rue St-Charles Ouest Suite 550,Longueuil, Québec, Canada J4K 5G4 Date of Initial Authorization: NOV 13, 2015 Date of Revision: Sep 22, 2022 Submission Control Number: 263260 Page 2 of 32 _LUPIN-ESTRADIOL (17β-estradiol) _ RECENT MAJOR LABEL CHANGES 1 INDICATIONS, 1.1. Pediatrics, 1.2 Geriatrics 09/2022 2 CONTRAINDICATIONS 09/2022 3 SERIOUS WARNINGS AND PRECAUTIONS, Serious Warnings and Precautions Box 09/2022 4 DOSAGE AND ADMINISTRATION, 4.1 Dosing Considerations 09/2022 4 DOSAGE AND ADMINISTRATION, 4.2 Recommended Dose and Dosage Adjustment 09/2022 4 DOSAGE AND ADMINISTRATION, 4.5 Missed Dose 09/2022 7 WARNINGS AND PRECAUTIONS, General 09/2022 7 WARNINGS AND PRECAUTIONS, Hyperlipoproteinemia / Hyperglycemia 09/2022 7 WARNINGS AND PRECAUTIONS, Monitoring and Laboratory Tests 09/2022 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED . RECENT MAJOR LABEL CHANGES....................................................Error! Bookmark not defined. TABLE OF CONTENTS ................................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION......................................................................... 4 1 INDICATIONS ................................................................................................................. 4 1.1 Pediatrics............................................................................................................. 4 1.2 Geriatrics.............................................................................................................. 4 2 CONTRAINDICATIONS.................................................................................................... Read the complete document